Taro Receives Approval for Ciclopirox Topical Suspension USP, 0.77% ANDA; Generic Equivalent to Loprox(R) Topical Suspension, 0.77%.

HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," Nasdaq: TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA") has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ciclopirox Topical Suspension USP, 0.77% ("ciclopirox topical suspension").

Taro's ciclopirox topical suspension is a prescription pharmaceutical product used for the treatment of fungal infections of the skin. The Taro product is bioequivalent to Medicis Pharmaceutical Corp.'s Loprox(R) Topical Suspension, 0.77%. According to industry sources, ciclopirox topical suspension products had annual U.S. sales of approximately $34.2 million.

Taro USA also markets Ciclopirox Olamine Cream USP, 0.77%. Taro and its subsidiaries manufacture and market a broad line of prescription and over-the-counter antifungal products.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro, please visit www.taro.com.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's ciclopirox products and other antifungal products. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include industry and market conditions; slower than anticipated penetration of new markets; physician, pharmacist or patient acceptance of Taro's ciclopirox products and other antifungal products; changes in the Company's financial position; regulatory actions; and, other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.